DK1377164T3 - Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo - Google Patents

Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo

Info

Publication number: DK1377164T3
Authority: DK; Denmark
Prior art keywords: erythropoietin; ameliorates; chemotherapy; vivo; induced toxicity
Prior art date: 2001-04-09

Application number

DK02725577T

Other languages

English (en)

Inventor

George Sigounas

Paul Mehlhop

Original Assignee

Univ East Carolina

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-09

Filing date

2002-04-08

Publication date

2008-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23082337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1377164(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-08 Application filed by Univ East Carolina filed Critical Univ East Carolina

2008-10-13 Application granted granted Critical

2008-10-13 Publication of DK1377164T3 publication Critical patent/DK1377164T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Toxicology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

DK02725577T 2001-04-09 2002-04-08 Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo DK1377164T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28262101P	2001-04-09	2001-04-09
PCT/US2002/011081 WO2002080676A1 (en)	2001-04-09	2002-04-08	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Publications (1)

Publication Number	Publication Date
DK1377164T3 true DK1377164T3 (da)	2008-10-13

Family

ID=23082337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02725577T DK1377164T3 (da)	2001-04-09	2002-04-08	Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo

Country Status (22)

Country	Link
US (2)	US20020169128A1 (da)
EP (1)	EP1377164B1 (da)
JP (1)	JP4428924B2 (da)
KR (1)	KR100885525B1 (da)
CN (2)	CN100379446C (da)
AT (1)	ATE399020T1 (da)
AU (1)	AU2002256133B2 (da)
BR (1)	BR0208727A (da)
CA (1)	CA2443025A1 (da)
DE (1)	DE60227244D1 (da)
DK (1)	DK1377164T3 (da)
ES (1)	ES2309166T3 (da)
HU (1)	HUP0303838A3 (da)
IL (3)	IL158155A0 (da)
MX (1)	MXPA03009182A (da)
NO (1)	NO20034504L (da)
NZ (1)	NZ528675A (da)
PL (1)	PL373361A1 (da)
PT (1)	PT1377164E (da)
RU (1)	RU2296563C2 (da)
WO (1)	WO2002080676A1 (da)
ZA (1)	ZA200307803B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ES2529300T3 (es)	2000-04-12	2015-02-18	Novozymes Biopharma Dk A/S	Proteínas de fusión de albúmina
WO2003060071A2 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
JP4266028B2 (ja) *	2003-05-12	2009-05-20	アフィーマックス・インコーポレイテッド	エリスロポエチン受容体に結合する新規ペプチド
MXPA05012314A (es) *	2003-05-12	2006-04-18	Affymax Inc	Radical separador para peptido modificado con polietilenglicol.
WO2004101600A2 (en) *	2003-05-12	2004-11-25	Affymax, Inc.	Novel poly(ethylene glycol) modified compounds and uses thereof
PT1625156E (pt) *	2003-05-12	2013-01-09	Affymax Inc	Novos péptidos que se fixam ao receptor da eritropoietina
US20080312201A1 (en) *	2004-09-10	2008-12-18	Patrick Fogarty	Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
WO2006060148A2 (en) *	2004-11-11	2006-06-08	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7550433B2 (en)	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
CA2661054A1 (en) *	2006-08-22	2008-02-28	Chugai Seiyaku Kabushiki Kaisha	Prophylactic and/or therapeutic agents for peripheral neuropathy
US20080249001A1 (en) *	2006-10-25	2008-10-09	Ajinomoto Co. Inc.	Agents that alleviate side-effects caused by chemotherapy agents
EP1992355A1 (en) *	2007-05-16	2008-11-19	Eberhardt Spanuth	Pharmaceutical combination medication comprising NSAIDs or cytoxic drugs
RU2410095C2 (ru) *	2009-04-20	2011-01-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Средство для повышения эффективности и снижения токсичности противоопухолевых препаратов
ES2917884T3 (es) *	2015-06-18	2022-07-12	Yeda Res & Dev	Protocolos de acondicionamiento y uso de los mismos para la regeneración de tejidos
US10695402B2 (en)	2017-03-16	2020-06-30	University Of Rochester	Erythropoietin for gastrointestinal dysfunction
WO2022159414A1 (en)	2021-01-22	2022-07-28	University Of Rochester	Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4859765A (en) *	1983-10-17	1989-08-22	Syntex (U.S.A.) Inc.	Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4863857A (en) *	1985-03-01	1989-09-05	Board Of Regents, The University Of Texas System	Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ215865A (en) *	1985-04-22	1988-10-28	Commw Serum Lab Commission	Method of determining the active site of a receptor-binding analogue
IT210425Z2 (it) *	1987-01-22	1988-12-30	Erga Srl	Portachiavi con mezzo di scrittura telescopico incorporato
US4853871A (en) *	1987-04-06	1989-08-01	Genex Corporation	Computer-based method for designing stablized proteins
US4856871A (en) *	1987-08-31	1989-08-15	General Electric Company	Replaceable laser and lens assembly
JP2632014B2 (ja) *	1988-03-03	1997-07-16	中外製薬株式会社	骨髄機能障害性貧血治療剤
GB9613070D0 (en) *	1996-06-21	1996-08-28	Rowett Research Services Limit	Dietary lectins
US20020052309A1 (en) *	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
US6719977B1 (en) *	1998-02-12	2004-04-13	The General Hospital Corporation	Methods to potentiate cancer therapies
MXPA01011429A (es) *	1999-05-11	2003-09-10	Ortho Mcneil Pharm Inc	Modelado farmacocinetico y farmacodinamico de administracion de eritropoyetina.
US6531121B2 (en) *	2000-12-29	2003-03-11	The Kenneth S. Warren Institute, Inc.	Protection and enhancement of erythropoietin-responsive cells, tissues and organs

2002
- 2002-04-05 US US10/117,011 patent/US20020169128A1/en not_active Abandoned
- 2002-04-08 CN CNB028078136A patent/CN100379446C/zh not_active Expired - Fee Related
- 2002-04-08 PL PL02373361A patent/PL373361A1/xx not_active Application Discontinuation
- 2002-04-08 AT AT02725577T patent/ATE399020T1/de not_active IP Right Cessation
- 2002-04-08 BR BR0208727-8A patent/BR0208727A/pt not_active IP Right Cessation
- 2002-04-08 CA CA002443025A patent/CA2443025A1/en not_active Abandoned
- 2002-04-08 CN CNA2007101533855A patent/CN101152565A/zh active Pending
- 2002-04-08 DE DE60227244T patent/DE60227244D1/de not_active Expired - Lifetime
- 2002-04-08 WO PCT/US2002/011081 patent/WO2002080676A1/en not_active Ceased
- 2002-04-08 MX MXPA03009182A patent/MXPA03009182A/es active IP Right Grant
- 2002-04-08 HU HU0303838A patent/HUP0303838A3/hu unknown
- 2002-04-08 EP EP02725577A patent/EP1377164B1/en not_active Revoked
- 2002-04-08 IL IL15815502A patent/IL158155A0/xx unknown
- 2002-04-08 JP JP2002578724A patent/JP4428924B2/ja not_active Expired - Fee Related
- 2002-04-08 KR KR1020037013132A patent/KR100885525B1/ko not_active Expired - Fee Related
- 2002-04-08 NZ NZ528675A patent/NZ528675A/en unknown
- 2002-04-08 DK DK02725577T patent/DK1377164T3/da active
- 2002-04-08 AU AU2002256133A patent/AU2002256133B2/en not_active Ceased
- 2002-04-08 ES ES02725577T patent/ES2309166T3/es not_active Expired - Lifetime
- 2002-04-08 PT PT02725577T patent/PT1377164E/pt unknown
- 2002-04-08 RU RU2003132584/14A patent/RU2296563C2/ru not_active IP Right Cessation
2003
- 2003-09-29 IL IL158155A patent/IL158155A/en not_active IP Right Cessation
- 2003-10-06 ZA ZA200307803A patent/ZA200307803B/en unknown
- 2003-10-08 NO NO20034504A patent/NO20034504L/no not_active Application Discontinuation
2009
- 2009-05-17 IL IL198783A patent/IL198783A0/en unknown
2011
- 2011-03-31 US US13/077,335 patent/US20110195046A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1377164A4 (en)	2005-05-04
HUP0303838A2 (hu)	2004-03-01
ES2309166T3 (es)	2008-12-16
PT1377164E (pt)	2008-09-30
ATE399020T1 (de)	2008-07-15
CN101152565A (zh)	2008-04-02
US20110195046A1 (en)	2011-08-11
NO20034504L (no)	2003-12-09
RU2003132584A (ru)	2005-04-10
DE60227244D1 (de)	2008-08-07
PL373361A1 (en)	2005-08-22
KR100885525B1 (ko)	2009-02-26
MXPA03009182A (es)	2004-02-17
EP1377164A1 (en)	2004-01-07
US20020169128A1 (en)	2002-11-14
JP4428924B2 (ja)	2010-03-10
IL158155A (en)	2009-12-24
RU2296563C2 (ru)	2007-04-10
JP2004532840A (ja)	2004-10-28
WO2002080676A1 (en)	2002-10-17
CA2443025A1 (en)	2002-10-17
AU2002256133B2 (en)	2007-05-31
NZ528675A (en)	2006-10-27
KR20030087064A (ko)	2003-11-12
IL158155A0 (en)	2004-03-28
IL198783A0 (en)	2010-02-17
NO20034504D0 (no)	2003-10-08
HUP0303838A3 (en)	2010-03-29
CN100379446C (zh)	2008-04-09
EP1377164B1 (en)	2008-06-25
CN1499927A (zh)	2004-05-26
BR0208727A (pt)	2005-05-10
ZA200307803B (en)	2005-02-09

Publication	Publication Date	Title
IL198783A0 (en)	2010-02-17	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
SE0001899D0 (sv)	2000-05-22	New compounds
CY1108532T1 (el)	2014-04-09	Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
SE0301882D0 (sv)	2003-06-25	New use I
ATE469136T1 (de)	2010-06-15	Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
SE0301886D0 (sv)	2003-06-25	New use V
DE60336664D1 (de)	2011-05-19	Nichtnukleosidische reverse-transkriptase-hemmer
MX2007000028A (es)	2007-07-20	Derivados de nicotinamida y su uso como agentes terapeuticos.
EA200300503A1 (ru)	2004-12-30	Новые лекарственные композиции на основе солей тиотропия и солей салметерола
NO20040096L (no)	2004-02-05	Taxol-forbedringsforbindelser
TNSN06377A1 (en)	2008-02-22	Combinations of glycopyrrolate and beta2 adrenoceptor agonists
SE0402762D0 (sv)	2004-11-11	Indazole sulphonamide derivatives
SE0102055D0 (sv)	2001-06-08	New Compounds
DE502005010427D1 (de)	2010-12-02	Physiologisch aktive zusammensetzung gegen diabetes
ATE333901T1 (de)	2006-08-15	Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
PL360492A1 (en)	2004-09-06	Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
EE05241B1 (et)	2009-12-15	Distamtsiini a-halogenoakrlolderivaadi kasutamine
SE0004101D0 (sv)	2000-11-09	New use
BRPI0407335A (pt)	2006-01-10	Agentes antibacterianos
RU2007122391A (ru)	2008-12-20	S-миртазапин для лечения приливов
MXPA05008711A (es)	2005-10-05	Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
UA95299C2 (ru)	2011-07-25	Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
DE50005714D1 (de)	2004-04-22	Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
EP1930023A3 (en)	2008-08-06	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
UY27376A1 (es)	2003-02-28	Formulación de medicamento que contiene un antagonista de ltb4